LG Chem Builds Dedicated Clinical Drug Manufacturing Plant in Osong

Speed of New Drug Development Business

[Asia Economy Reporter Hwang Yoon-joo] LG Chem is accelerating its new drug development business.

According to industry sources on the 13th, LG Chem has established an additional dedicated production plant for clinical trial drugs on the site of its Osong plant in Chungbuk. The Osong plant is LG Chem's flagship facility producing biopharmaceuticals such as growth hormones, antibody drugs, vaccines, as well as synthetic drugs like Gemigliptin.

The new plant is a two-story building with a total floor area of 7,220㎡, and approximately 63 billion KRW was invested. LG Chem began construction in June 2019. At this site, LG Chem will produce clinical trial biopharmaceuticals and research scale-up (mass production) methods. It will also produce finished clinical synthetic drugs and develop processes.

With the establishment of this plant, LG Chem's new drug development business is expected to gain momentum. Typically, clinical trial drugs are produced by contract manufacturing organizations (CMOs), making timely use difficult, but having an in-house plant can resolve these issues.